Editor-in-Chief
Napoleone Ferrara

Deputy Editors
Stephen W. Fesik
Paul Workman

Senior Editors
Ian Collins
Tejal Desai
Peter J. Houghton
Candace S. Johnson
John S. Lazo
Guillermina Lozano
Brion W. Murray
Dario Neri
Martine F. Roussel
Peter Senter
Beverly A. Teicher

Editorial Board

Robert T. Abraham
Rajesh Agarwal
Adriana Albini
Kari Alitalo
Suresh V. Ambudkar
Paul A. Andrews
Avi Ashkenazi
André S. Bachmann
Raffaele Baffa
Rebecca G. Bagley
Albert S. Baldwin, Jr.
Laura E. Benjamin
Darell D. Bigner
Michael L. Bittner
Thomas F. Bumol
Robert M. Campbell
David A. Cheresh
James G. Christensen
Steve R. Coats
Barbara A. Conley
Robert A. Copeland
Sayed S. Daoud
Marcia I. Dawson
William A. Denny
Paul Dent
Channing J. Der
Visha M. Dixit
Ethan Dmitrovsky
Suzanne A. Eccles
Heinz-Herbert Fiebig
William D. Figg, Sr.
Arthur E. Frankel
Stephen V. Frye
Simone Fulda
Susan M. Galbraith
Ram N. Ganapathi
Michelle D. Garrett
Andreas J. Gescher
David A. Gewirtz
Amato J. Giaccia
I. David Goldman
Michael M. Gottesman
Lorraine J. Gudas
Stephen B. Howell
Rakesh K. Jain
Peter A. Jones
Craig T. Jordan
Juliane M. Jürgensmeier
Robert S. Kerbel
Donald W. Kufe
Michihiko Kuwano
Daruka Mahadevan
Sridhar Mani
Lawrence D. Mayer
David J. McConkey
Frank McCormick
Giovanni Melillo
Ira Mellman
Paul S. Mischel
Brett P. Monia
Robert A. Newman
Barry R. O’Keefe
Pier Paolo Pandolfi
Ira Pastan
Maurizio Pellecchia
Yves Pommier
C. Patrick Reynolds
Edward A. Sausville
Jeffrey Settleman
Shivendra V. Singh
Bin Tean Teh
Carter Van Waes
Kristiina Vuori
Shaomeng Wang
David J. Waxman
Tai Wai Wong
Amy E. Wright
Leigh S. Zawel
Yuesheng Zhang

Editorial Office: Molecular Cancer Therapeutics [ISSN: 1535-7163 (Print); ISSN: 1538-8514 (Online)] is published monthly, one volume per year, by the American Association for Cancer Research, Inc. Periodicals postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to Molecular Cancer Therapeutics, AACR Member Services, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404 or E-mail: membership@aacr.org. Copyright 2018 by the American Association for Cancer Research, Inc. The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).
Molecular Cancer Therapeutics
Publishing Information

AACR Officers
Michael A. Caligiuri, President
Elizabeth M. Jaffee, President-Elect
Nancy E. Davidson, Past President
William N. Hait, Treasurer
Margaret Foti, Chief Executive Officer

Publications Committee
Victor E. Velculescu, Chairperson
Dafna Bar-Sagi
Mary Helen Barcellos-Hoff
Michael E. Berens
John D. Carpten
Maura L. Gillison
Rakesh K. Jain
Pasi A. Jänne
Gerrit A. Meijer
Gordon B. Mills
Steffi Oesterreich
William Pao
Gloria M. Peterson
David R. Piwnica-Worms
Charles W.M. Roberts
Alice T. Shaw
Lillian L. Siu
Saraswati V. Sukumar
Toshikazu Ushijima

Scope
Molecular Cancer Therapeutics strives to be the top choice for publishing the best science in the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanisms of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms. The journal’s main focus is on small molecule and protein drugs, other molecular entities may be considered.

Molecular Cancer Therapeutics is abstracted and/or indexed in Current Contents/Clinical Medicine, MEDLINE, Science Citation Index, Scopus, and Web of Science.

Submission of Manuscripts
Online manuscript submission is welcomed at http://mct.msubmit.net. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal’s home page at http://mct.aacrjournals.org.

Publication Charges
Beginning with manuscripts submitted January 1, 2016 or after, articles will be published with the understanding that the author(s) will pay both a publication fee plus a color figure handling fee. Please see the Instructions for Authors, which are available from the Journal’s home page at http://mct.aacrjournals.org.

Subscription Information
Nonmember Individuals
Subscriptions include print version with online access. Contacts listed below are for nonmember individual subscriptions.

USA and Rest of World (excluding Japan)
American Association for Cancer Research, 615 Chestnut Street, Philadelphia, PA 19106; 1-855-744-4667; pubsales@aacr.org

Japan
e-support@manuzen.co.jp; journal@kinokuniya.co.jp; usaco@usaco.co.jp

International print subscriptions include cost of surface mail. Expedited mailing is available. Contact the American Association for Cancer Research for rates.

Site Licenses
For information about institutional site licenses, contact pubsales@aacr.org.

AACR Members
AACR members may opt to receive either a print subscription with online access to content or an online-only subscription. Contact membership@aacr.org or visit the membership page at www.aacr.org for more information.

Single Issue Sales
Subject to their availability, single or back issues may be purchased for $60 (U.S.) or $63 (outside the U.S.) each. The cost must be prepaid. Contact pubsales@aacr.org.

Claims
One-time claims for missing issues made within 120 days of the issue’s publication will be honored, subject to availability. No credit or refund will be given if an issue is out of print at the time of claim.

AACR Members
membership@aacr.org

Nonmembers and Institutions
pubsales@aacr.org

Advertising Information
For information about advertising in AACR journals, contact Pharmaceutical Media Inc., 30 East 33rd St., 4th Floor, New York, NY 10016; 212-904-0360; Dsimone@pminy.com

Copyright and Permissions
Content printed in or disseminated by Molecular Cancer Therapeutics is protected by copyright. Authors who wish to publish material in Molecular Cancer Therapeutics must formally transfer copyright to the AACR. All authors must sign copyright transfer forms before the AACR can proceed with publication.

To read the complete AACR Copyright and Permissions Policy, visit http://aacrjournals.org/content/authors/copyright-permissions-and-access.